AZD2962
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 18, 2025
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting | Phase classification: P1/2 ➔ P1 | Initiation date: Jul 2025 ➔ Nov 2025
Enrollment open • Monotherapy • Phase classification • Trial initiation date • Hematological Malignancies • Oncology
1 to 1
Of
1
Go to page
1